Stanek J, Caravatti G, Frei J, Furet P, Mett H, Schneider P, Regenass U
Research Laboratory, Ciba-Geigy AG, Basel, Switzerland.
J Med Chem. 1993 Jul 23;36(15):2168-71. doi: 10.1021/jm00067a014.
Two isomeric amidino-2-acetylpyridine amidinohydrazones, 11 and 12, and 4-amidinoindanone amidinohydrazone, 17, have been synthesized and tested for inhibition of S-adenosylmethionine decarboxylase (SAMDC) and diamine oxidase and for antiproliferative activity against T24 human bladder carcinoma cells. Compound 11 inhibited SAMDC with an IC50 of 10 nM and was 140- and > 500-fold more potent than methylglyoxal bis(guanylhydrazone) (MGBG) and 12, respectively. The difference in potency between 11 and 12 was interpreted with the help of molecular modeling and appeared to be associated with two different low-energy conformations of the compounds. Compound 17 which represents a conformationally constrained analogue of 11, was superior to the latter and MGBG with respect to selective inhibition of SAMDC and antiproliferative activity, and is of interest as a potential anticancer agent and a drug for the treatment of protozoal and Pneumocystis carinii infections.
已合成了两种异构的脒基 - 2 - 乙酰吡啶脒腙(11和12)以及4 - 脒基茚满酮脒腙(17),并测试了它们对S - 腺苷甲硫氨酸脱羧酶(SAMDC)和二胺氧化酶的抑制作用以及对T24人膀胱癌细胞的抗增殖活性。化合物11对SAMDC的抑制IC50为10 nM,分别比甲基乙二醛双(胍腙)(MGBG)和12强140倍和> 500倍。借助分子建模解释了11和12之间效力的差异,这似乎与化合物的两种不同低能量构象有关。化合物17代表11的构象受限类似物,在SAMDC的选择性抑制和抗增殖活性方面优于后者和MGBG,作为潜在的抗癌剂以及用于治疗原生动物和卡氏肺孢子虫感染的药物具有研究价值。